Reevaluation of the Role of Duration of Morning Stiffness in the Assessment of Rheumatoid Arthritis Activity
Authors:
- Nasim A KhanNKNasim A Khan
- Yusuf YaziciYYYusuf Yazici
- Jaime Calvo-AlenJCJaime Calvo-Alen
- Jolanta DadonieneJDJolanta Dadoniene
- Laure GossecLGLaure Gossec
- Troels M HansenTHTroels M Hansen
- Margriet HuismanMHMargriet Huisman
- Riina KallikormRKRiina Kallikorm
- Raili MullerRMRaili Muller
- Margareth LivebornMLMargareth Liveborn
- Rolf OdingRORolf Oding
- Elena LuchikhinaELElena Luchikhina
- 15 October 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (11) , 2435-2442
Abstract
Objective.: To evaluate the utility of the duration of morning stiffness (MS), as a patient-reported outcome (PRO), in assessing rheumatoid arthritis (RA) disease activity.Methods.: We acquired information on 5439 patients in QUEST-RA, an international database of patients with RA evaluated by a standard protocol. MS duration was assessed from time of waking to time of maximal improvement. Ability of MS duration to differentiate RA activity states, based on Disease Activity Score (DAS)28, was assessed by analysis of variance; and a receiver-operating characteristic (ROC) curve was plotted for discriminating clinically active (DAS28 > 3.2) from less active (DAS28 ≤ 3.2) RA. Mixed-effect analysis of covariance (ANCOVA) models were used to assess the utility of adding MS duration to Routine Assessment of Patient Index Data (RAPID)3, a PRO index based on physical function, pain, and general health (GH), in predicting the 3-variable DAS28 (DAS28v3).Results.: MS duration had moderate correlation (r = 0.41–0.48) with pain, Health Assessment Questionnaire, and GH; and weak correlation (r = 0.23–0.39) with joint counts and erythrocyte sedimentation rate. MS duration differed significantly among patients with different RA activity (p < 0.001). The area under the ROC curve of 0.74 (95% CI 0.72–0.75) showed moderate ability of MS duration to differentiate clinically active from less active RA. ANCOVA showed significant interactive effects between RAPID3 and the MS duration categories (p = 0.0005) in predicting DAS28v3. The effect of MS was found to be clinically important in patients with the low RAPID3 scores (< 6) in whom the presence of MS may indicate clinically active disease (DAS28v3 > 3.2).Conclusion.: MS duration has a moderate correlation with RA disease activity. Assessment of MS duration may be clinically helpful in patients with low RAPID3 scores.Keywords
This publication has 27 references indexed in Scilit:
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritisRheumatology, 2007
- Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteriaRheumatology, 2005
- A simplified disease activity index for rheumatoid arthritis for use in clinical practiceRheumatology, 2003
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Feasibility and validity of the RADAI, a self‐administered rheumatoid arthritis disease activity indexRheumatology, 2000
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials controlled NSAID trialsJournal of Clinical Epidemiology, 1990
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Preliminary criteria for clinical remission in rheumatoid arthritisArthritis & Rheumatism, 1981